Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a ...
A spatial transcriptomics study links depletion of non-tumoral B cells to relapse risk in classical Hodgkin lymphoma and ...
Laboratory experiments with human tonsil-derived fibroblasts show that senescent lymphoid stromal cells suppress B cell ...
B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...
Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage.Dublin, Oct. (GLOBE NEWSWIRE) -- "Diffuse Large B-Cell ...
B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...
A phase I trial of OX40-enhanced CAR-T therapy showed remissions in several B-cell non-Hodgkin lymphomas, researchers reported.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results